Article
Glucosylceramide synthase inhibition with lucerastat lowers globotriaosylceramide and lysosome staining in cultured fibroblasts from Fabry patients with different mutation types.
Human molecular genetics - 1 Oct 2018
Welford R W D, Mühlemann A, Garzotti M, Rickert V, Groenen P M A, Morand O, Üçeyler N, Probst M R
Abstract excerpt
Fabry disease is an X-linked lysosomal storage disorder caused by mutations in the GLA gene coding for α-galactosidase A (α-GalA). The deleterious mutations lead to accumulation of α-GalA substrates, including globotriaosylceramide (Gb3) and globotriaosylsphingosine. Progressive glycolipid storage results in cellular dysfunction, leading to organ damage and clinical disease, i.e. neuropathic pain, impaired renal...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.